Document Detail


Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults.
MedLine Citation:
PMID:  20732465     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
The mechanisms of immune response following yellow fever (YF-17DD) vaccination are still poorly understood. In this study, we have performed a longitudinal investigation (days 0, 7, 15 and 30) to characterize the cytokine profile of innate and adaptive immunity following YF-17DD first-time vaccination. Data from non-stimulated cultures demonstrated a prominent participation of the innate immunity with increased frequency of TNF-α(+) neutrophils and IFN-γ(+) NK-cells at day 7 besides TNF-α(+) monocytes at day 7, day 15 and day 30. Increased frequency of IL-10(+) monocytes was observed at day 15 and day 30, and decreased percentage of IL-4(+) NK-cells were detected at day 7, day 15 and day 30. Time-dependent and oscillating cytokine pattern was observed in CD4(+) T-cells, with low percentage of IL-12(+), IL-4(+) and IL-10(+) cells at day 7 and increased frequency of TNF-α(+) cells at day 15 besides IFN-γ(+) and IL-5(+) cells at day 15 and day 30. Later changes with increased percentage of IL-12(+) and IL-5(+)CD8(+) T-cells were observed at day 30. Increased frequency of IL-10(+) B-cells was observed at day 15, when seroconversion was detected in all vaccinees. The overall cytokine analysis of non-stimulated leukocytes showed a transient shift towards a pro-inflammatory profile at day 7, mainly due to changes in the innate immunity, which draws back toward a mixed/regulatory pattern at day 15 and day 30. The changes induced by the in vitro YF-17DD vaccine-stimulation were mainly observed at day 0 and day 7 (before seroconversion) with minor changes at day 15 and day 30 (after seroconversion). These data support the hypothesis that a complex network with mixed pro/anti-inflammatory cytokine profile is associated with the establishment of the protective immunity following YF-17DD primo-vaccination, free of adverse events.
Authors:
Maria Luiza Silva; Marina Angela Martins; Luçandra Ramos Espírito-Santo; Ana Carolina Campi-Azevedo; Denise Silveira-Lemos; José Geraldo Leite Ribeiro; Akira Homma; Erna Geessien Kroon; Andréa Teixeira-Carvalho; Silvana Maria Elói-Santos; Olindo Assis Martins-Filho
Related Documents :
20331905 - Ganedenbc30 cell wall and metabolites: anti-inflammatory and immune modulating effects ...
11587525 - Differential regulation of interleukin-12 and interleukin-10 by heat shock response in ...
8683105 - Il-10 production is enhanced in human t cells by il-12 and il-6 and in monocytes by tum...
19702865 - Intermediate chains of exopolysaccharides from lactobacillus rhamnosus rw-9595m increas...
15899055 - The active metabolite of leflunomide, a77 1726, interferes with dendritic cell function.
11871495 - Topical immunomodulators--progress towards treating inflammation, infection, and cancer.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-08-21
Journal Detail:
Title:  Vaccine     Volume:  29     ISSN:  1873-2518     ISO Abbreviation:  Vaccine     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8406899     Medline TA:  Vaccine     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  583-92     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Ltd. All rights reserved.
Affiliation:
Laboratório de Biomarcadores de Diagnóstico e Monitoração, Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Flutracking provides a measure of field influenza vaccine effectiveness, Australia, 2007-2009.
Next Document:  Immunological fingerprinting of group B streptococci: from circulating human antibodies to protectiv...